Cryopep hemostasis coagulation - Human FVIII congenital deficient plasma with Anti-VIII inhibitor (Bethesda)

HEMOSTASIS COAGULATION RESEARCH DEFICIENT PLASMAS CONGENITAL DEFICIENT PLASMAS (BOTTLES)

Human FVIII congenital deficient plasma with Anti-VIII inhibitor (Bethesda)

Plasma from a single human donor with congenital Factor VIII deficiency with anti-VIII inhibitor.
Packaging in bottle. The minimum packaged volume is 50 mL. The price offer is based on the volume requested.

Reference	6-PPD08C-INH
Presentation	Vial
Format	Minimum 50 mL
Quote

Price list, safety data sheets and notices are accessible to our registered customers.

Reference	Presentation	Format	Quote	Product sheet
6-PPD08C-INH	Vial	Minimum 50 mL

Price list, safety data sheets and notices are accessible to our registered customers.

Factor VIII is a glycoprotein mainly synthesized by the liver. It circulates in the plasma in the form bound to VWF which protects it from rapid proteolytic degradation. It is activated by FXa or thrombin in FVIIIa which will complex with FIXa in the presence of phospholipids to activate FX in FXa.
A patient who is deficient in FVIII has hemophilia A.

Special plasmas are derived from patients with a congenital deficiency, severe or moderate, or presenting a particular profile.
No buffer or preservatives are added. Quickly frozen at -80° C, the plasma maintains perfectly intact the matrix.
All plasmas are stable when stored at -40° C to -80° C.
We carefully pack with dry ice during shipment.
No additive or preservative.
Expiry date > 1 year.
Plastic vials.

Minimize test time.
Ready to use.

Human Factor VIII congenital deficient plasma (severe <1%)
Human Factor VIII congenital deficient plasma >5%
Plasma Factor VIII deficient chemically depleted

	These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
	These kits are intended for in vitro diagnostic use.
	These kits are for research use only and are not intended to be used for diagnostic procedures.
	Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
	Biological risk products.
	Storage between 2 and 8 ° C.
	Reactive in liquid form.
	Reactive in lyophilized form.
	Reactive in frozen form.
	Stability after opening at 2-8 ° C.
	Products that can be refrozen.
	Stability 12 months after refreezing at -20 ° C.
	Manufacturer.
	Importer
	Distributor.

HEMOSTASIS COAGULATION RESEARCH DEFICIENT PLASMAS CONGENITAL DEFICIENT PLASMAS (BOTTLES)

Human FVIII congenital deficient plasma with Anti-VIII inhibitor (Bethesda)

Price list, safety data sheets and notices are accessible to our registered customers.

Price list, safety data sheets and notices are accessible to our registered customers.

Cryopep Catalogue
Thrombosis Haemostasis 2024

Cryopep Catalogue
Haemostasis Research 2024

Cryopep DEFICIENT PLASMAS

Product sheet Human FVIII congenital deficient plasma with Anti-VIII inhibitor (Bethesda)

CRYOPEP

You must identify yourself to search for a certificate of analysis

HEMOSTASIS COAGULATION RESEARCH DEFICIENT PLASMAS CONGENITAL DEFICIENT PLASMAS (BOTTLES)

Human FVIII congenital deficient plasma with Anti-VIII inhibitor (Bethesda)

Product sheet

Price list, safety data sheets and notices are accessible to our registered customers.

Price list, safety data sheets and notices are accessible to our registered customers.

Cryopep CatalogueThrombosis Haemostasis 2024

Cryopep CatalogueHaemostasis Research 2024

Cryopep DEFICIENT PLASMAS

Product sheet Human FVIII congenital deficient plasma with Anti-VIII inhibitor (Bethesda)

Cryopep Catalogue
Thrombosis Haemostasis 2024

Cryopep Catalogue
Haemostasis Research 2024